CN1678302A - 取代的5－苯并二氢吡喃－5－基－乙胺化合物及其在治疗青光眼中的用途 - Google Patents

取代的5－苯并二氢吡喃－5－基－乙胺化合物及其在治疗青光眼中的用途 Download PDF

Info

Publication number
CN1678302A
CN1678302A CNA038202239A CN03820223A CN1678302A CN 1678302 A CN1678302 A CN 1678302A CN A038202239 A CNA038202239 A CN A038202239A CN 03820223 A CN03820223 A CN 03820223A CN 1678302 A CN1678302 A CN 1678302A
Authority
CN
China
Prior art keywords
alkyl
halogen
hydrogen
alkoxyl
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038202239A
Other languages
English (en)
Chinese (zh)
Inventor
J·A·梅
A·P·丹塔纳拉亚纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of CN1678302A publication Critical patent/CN1678302A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
CNA038202239A 2002-08-30 2003-08-27 取代的5－苯并二氢吡喃－5－基－乙胺化合物及其在治疗青光眼中的用途 Pending CN1678302A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40721002P 2002-08-30 2002-08-30
US60/407,210 2002-08-30

Publications (1)

Publication Number Publication Date
CN1678302A true CN1678302A (zh) 2005-10-05

Family

ID=31978438

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038202239A Pending CN1678302A (zh) 2002-08-30 2003-08-27 取代的5－苯并二氢吡喃－5－基－乙胺化合物及其在治疗青光眼中的用途

Country Status (13)

Country Link
US (1) US20050171190A1 (enExample)
EP (1) EP1545501A2 (enExample)
JP (1) JP2006501245A (enExample)
KR (1) KR20050033654A (enExample)
CN (1) CN1678302A (enExample)
AR (1) AR041080A1 (enExample)
AU (1) AU2003262931B2 (enExample)
BR (1) BR0314419A (enExample)
CA (1) CA2495192A1 (enExample)
MX (1) MXPA05002259A (enExample)
PL (1) PL375564A1 (enExample)
WO (1) WO2004019874A2 (enExample)
ZA (1) ZA200501288B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
BR0316775A (pt) 2002-12-13 2005-11-01 Alcon Inc Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
US7476687B2 (en) * 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
DE68929435T2 (de) * 1988-09-06 2003-07-17 Pharmacia Ab, Stockholm Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
AU1928892A (en) * 1991-06-21 1993-01-25 Smithkline Beecham Plc Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5290781A (en) * 1993-01-05 1994-03-01 Iolab Corporation Ketaneserinol as an agent to reduce intraocular pressure
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US5538974A (en) * 1994-01-27 1996-07-23 Senju Pharamceutical Co., Ltd. Ophthalmic composition for lowering intraocular pressure
ATE166227T1 (de) * 1994-03-18 1998-06-15 Senju Pharma Co Sarpogrelat enthaltende opthalmologische zubereitungen zur senkung des intraokularen druckes
US5874477A (en) * 1994-08-12 1999-02-23 The University Of Hawaii Method of treatment for malaria utilizing serotonin receptor ligands
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
DK0901483T3 (da) * 1996-05-14 2003-11-03 Glaxo Group Ltd Benzofuraner og benzopyraner som kronobiologiske midler
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
US6107324A (en) * 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
GB9819019D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
AU755119B2 (en) * 1998-09-18 2002-12-05 Alcon Laboratories, Inc. Serotonergic 5HT2 agonists for treating glaucoma
CA2361516A1 (en) * 1999-01-27 2000-08-03 Jeffrey Thomas Mullaney Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
WO2000077001A1 (en) * 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
WO2001070705A1 (en) * 2000-03-17 2001-09-27 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US6806285B1 (en) * 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
ATE318821T1 (de) * 2001-06-01 2006-03-15 Alcon Inc Pyranoindazole und ihre verwendung in der glaukombehandlung
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma

Also Published As

Publication number Publication date
AR041080A1 (es) 2005-04-27
US20050171190A1 (en) 2005-08-04
MXPA05002259A (es) 2005-07-05
WO2004019874A2 (en) 2004-03-11
AU2003262931A1 (en) 2004-03-19
AU2003262931B2 (en) 2008-06-26
EP1545501A2 (en) 2005-06-29
JP2006501245A (ja) 2006-01-12
WO2004019874A3 (en) 2004-07-01
BR0314419A (pt) 2005-07-19
KR20050033654A (ko) 2005-04-12
ZA200501288B (en) 2005-09-05
CA2495192A1 (en) 2004-03-11
PL375564A1 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
CN100384417C (zh) 吡喃并吲唑类化合物及其用于制备治疗青光眼药物的用途
RU2004126613A (ru) Замещенные индолы в качестве агонистов альфа-1
US6933392B2 (en) Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
CN1512879A (zh) 新的芳氨基丙烷类似物及其用于治疗青光眼的用途
CN85101761A (zh) 新型色胺衍生物的制备方法和应用
CN1450994A (zh) 用于治疗青光眼的6－羟基－吲唑衍生物
JP2004532887A (ja) 新規な融合インダゾールおよびインドールおよび緑内障治療へのこれらの使用
CN1450995A (zh) 用于治疗青光眼的5－羟基吲唑衍生物
CN101035526A (zh) 用于治疗高眼压的眼用组合物
US20050171190A1 (en) Substituted 5-chroman-5-YL-ethylamine compounds and their use for the treatment of glaucoma
CN1301161A (zh) 用于治疗眼睛和中枢神经系统障碍的血清素激活的5ht7受体化合物
CN1268334C (zh) 新颖的苯并二呋喃咪唑啉和苯并呋喃咪唑啉衍生物及其用于制备治疗青光眼药物的用途
US7396856B2 (en) Benzopyran analogs and their use for the treatment of glaucoma
US20050277636A1 (en) Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7439262B1 (en) Substituted 1-alkylamino-1-H-indazoles for the treatment of glaucoma
US7425572B2 (en) Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
CN1051546C (zh) 新的1,1-双杂唑基烷烃衍生物及其作为神经保护剂的用途
CN1127501C (zh) 吲哚和2,3－二氢吲哚衍生物、它们的制备及用途
CN1901904A (zh) 1,2－二氮杂－二苯并[e,h]薁用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途
CN1304407A (zh) 用于治疗抑郁症的n－芳氧基乙基－吲哚基－烷基胺
CN1897938A (zh) 1，3－二氮杂－二苯并[e,h]薁用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication